Cancers, Vol. 16, Pages 1133: Topical Immunotherapy for Actinic Keratosis and Field Cancerization
Cancers, Vol. 16, Pages 1133: Topical Immunotherapy for Actinic Keratosis and Field Cancerization
Cancers doi: 10.3390/cancers16061133
Authors:
Laura Bernal Masferrer
Tamara Gracia Cazaña
Isabel Bernad Alonso
Marcial Álvarez-Salafranca
Manuel Almenara Blasco
María Gallego Rentero
Ángeles Juarranz de la Fuente
Yolanda Gilaberte
This comprehensive review delves into various immunotherapeutic approaches for the management of actinic keratoses (AKs), precancerous skin lesions associated with UV exposure. Although there are treatments whose main mechanism of action is immune modulation, such as imiquimod or diclofenac, other treatments, apart from their main effect on dysplastic cells, exert some immunological action, which in the end contributes to their efficacy. While treatments like 5-fluorouracil, imiquimod, photodynamic therapy, and nicotinamide are promising in the management of AKs, especially in immunocompetent individuals, their efficacy is somewhat reduced in solid organ transplant recipients due to immunosuppression. The analysis extends to optimal combination, focusing on cryoimmunotherapy as the most relevant. New immunotherapies include resimiquimod, ingenol disoxate, N-phosphonacetyl-L-aspartate (PALA), or anti-PD1 that have shown promising results, although more studies are needed in order to standardize their use.
Source: Cancers - Category: Cancer & Oncology Authors: Laura Bernal Masferrer Tamara Gracia Caza ña Isabel Bernad Alonso Marcial Álvarez-Salafranca Manuel Almenara Blasco Mar ía Gallego Rentero Ángeles Juarranz de la Fuente Yolanda Gilaberte Tags: Review Source Type: research
More News: Allergy & Immunology | Cancer | Cancer & Oncology | Diclofenac | Immunotherapy | Skin | Study | Transplants | Voltaren